Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.
Journal: Cancer discovery
Published: October 07, 2025
Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 27, 2025
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.
Journal: The Lancet. Oncology
Published: May 07, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 15, 2025
FOXJ1 mediates taxane resistance through regulation of microtubule dynamics.
Journal: Nature communications
Published: December 30, 2024
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 25, 2024
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.
Journal: Cell reports
Published: April 04, 2024
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.
Journal: Nature communications
Published: March 07, 2024
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.
Journal: The Journal of clinical investigation
Published: February 06, 2024
Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer.
Journal: bioRxiv : the preprint server for biology
Published: January 23, 2024
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.
Journal: Molecular cancer therapeutics
Published: December 29, 2023
Last Updated: 09/26/2026